Strategic Advisory · Ag-Bio Innovation
From Breakthrough to Broadacres.
Regulatory strategy, commercialization pathways, and market access for biological technologies — built by operators who have moved products from discovery through registration to revenue.
Three Disciplines. One Engagement.
Regulatory Architecture
Pathway design, jurisdiction sequencing, classification risk assessment, and regulatory narrative framing. Built from day one to align with your commercial and capital strategy.
Commercial Strategy
Market entry planning, portfolio prioritization, and commercialization sequencing grounded in regulatory reality, not built in a vacuum.
Product Development Governance
R&D program design, stage-gate governance, data package strategy, and development prioritization led by principals with decades of hands-on portfolio leadership.
The Problem We Solve
Biological technologies are advancing faster than the systems designed to bring them to market. Regulatory strategy is built without commercial context. Commercial plans lack regulatory grounding. Product development operates in isolation from both.
The result: delayed approvals, misallocated capital, and impaired valuation at precisely the moments that matter most. Frontier BioStrategy exists to close those gaps. Not by adding more advisors to the table, but by eliminating the need for separate ones.
Who We Work With
Emerging Biological Platforms
Seed-to-Series B synthetic biology and AI-native biological companies building the regulatory and commercial architecture to support their first market entries.
Growth-Stage Companies
Organizations scaling internationally that require strategic portfolio governance and cross-jurisdiction expansion planning.
Investors in Ag-Bio Innovation
Venture capital and private equity firms seeking independent regulatory and development risk assessment for biological assets under evaluation.
60+ Years Combined Executive Experience · 3 Founding Principals · Regulatory · Commercial · Scientific
Every engagement starts with a conversation, not a pitch.
We work with a select number of clients at any given time. If you are navigating the intersection of regulatory complexity, commercial strategy, and product development in biological technologies, we should talk.